Breaking the "Right" Gene promotes response to CAR-T cell therapy
One of the main problems with immunotherapy is that some people respond better than others to treatments. A patient’s striking response to CAR (Chimeric Antigen Receptor)-T cell based therapy in a recent clinical trial has encouraged researchers to go into the reasons for this unexpected success. There is something “broken” in this patient, which allowed CAR-T cells to induce remission of leukaemia: a gene called TET2 does not do its job. How does it affect response to treatment?